Skip to content
value.today
ReGenX Biosciences, LLC logo

ReGenX Biosciences, LLC

Total raised
$106 M
3 rounds on record
Latest round
$71 M
May 2015
First round on record
Oct 2013
Today
Went public
See the company page

ReGenX Biosciences, LLC is listed today as Regenxbio Inc.: market value, financials and filings are on its company page.

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of ReGenX Biosciences, LLC
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2015$71 MNo. 3$50 to $250 million

ReGenX Biosciences, LLC: Raise no. 3, May 2015

Investors in this round

36 investors had bought by the notice of May 28, 2015: 36 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for ReGenX Biosciences, LLC as a whole in other filings: see Investors below.

What the notice says

Amount sold
$71 M of $71 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$2,334,999
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Kenneth T. Mills · Executive Officer, Director
  • Allan M. Fox · Director
  • Benjamin T. Auspitz · Director
  • Camille J. Samuels · Director
  • Donald J. Hayden, Jr. · Director
  • Luke J. Beshar · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Chardan Capital Markets, LLC (CRD 120128) · broker-dealer Chardan Capital Markets, LLC (CRD 120128) · New York, New YorkSold in CA, CO, CT, MA, MD, NY

Signed by Kenneth T. Mills, President and Chief Executive Officer. Source: SEC Form D, newest notice filed May 28, 2015. Read the notice at the SEC.

equitySEC
Jan 2015$28 MNo. 2$10 to $50 million

ReGenX Biosciences, LLC: Raise no. 2, Jan 2015

Investors in this round

15 investors had bought by the notice of Jan 23, 2015: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for ReGenX Biosciences, LLC as a whole in other filings: see Investors below.

What the notice says

Amount sold
$28 M of $30 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Kenneth T. Mills · Executive Officer, Director
  • Allan M. Fox · Director
  • Benjamin T. Auspitz · Director
  • Donald J. Hayden, Jr. · Director
  • John Daniel Kiser · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Kenneth T. Mills, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 23, 2015. Read the notice at the SEC.

equitySEC
Oct 2013$8 MNo. 1$2 to $10 million

ReGenX Biosciences, LLC: Raise no. 1, Oct 2013

Investors in this round

3 investors had bought by the notice of Nov 7, 2013: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for ReGenX Biosciences, LLC as a whole in other filings: see Investors below.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Limited Liability Company, incorporated in Delaware

People named in the notice

  • Kenneth T. Mills · Executive Officer, Director
  • Allan T. Fox · Director
  • Daniel T. Kiser · Director
  • Don T. Hayden · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Kenneth T. Mills, President and CEO. Source: SEC Form D, newest notice filed Nov 7, 2013. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Regenxbio Inc., its revenue in fiscal 2025 came from these product and service lines: License and royalty $156.27 million (92%), Zolgensma and Itvisma Royalties $83.18 million (49%), Zolgensma Royalties $82.54 million (48%), Nippon Shinyaku Licenses $72.90 million (43%), Total Service Revenue $14.17 million (8%).

    Annual report (SEC XBRL) · Dec 2025

  • ReGenX Biosciences, LLC chose not to state its revenue in its newest notice of a funding round (May 2015).

    SEC Form D · May 2015

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · May 2015

Products and services#

No products or services of ReGenX Biosciences, LLC are on record.

Investors#

6 named in official filings. Open an investor to see everything it has backed.

Investors in ReGenX Biosciences, LLC
InvestorKindAmountRoundRoleSource
Deerfield Management Company, L.P.Fund or asset managernot statednot statedHeld Series C and D preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Deerfield Mgmt III, L.P.Fund or asset managernot statednot statedHeld Series C and D preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Deerfield Private Design Fund III, L.P.Fund or asset managernot statednot statedHeld Series C and D preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Donald J. Hayden Jr.Personnot statednot statedHeld Series C preferred stock, director (Form 3, 2015)SEC Form 3
Kenneth T. MillsPersonnot statednot statedHeld Series C preferred stock, director (Form 3, 2015)SEC Form 3
Vittal VasistaPersonnot statednot statedHeld Series C preferred stock (Form 3, 2015)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 36 investors.

Largest shareholders today

Institutions holding Regenxbio Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by ReGenX Biosciences, LLC
NameRoleNamed in
Kenneth T. MillsExecutive officerMay 2015
Allan M. FoxDirectorMay 2015
Benjamin T. AuspitzDirectorMay 2015
Camille J. SamuelsDirectorMay 2015
Donald J. Hayden, Jr.DirectorMay 2015
Kenneth T. MillsDirectorMay 2015
Luke J. BesharDirectorMay 2015
John Daniel KiserDirectorJan 2015
Allan T. FoxDirectorNov 2013
Daniel T. KiserDirectorNov 2013
Don T. HaydenDirectorNov 2013

Went public since 2015. Its SEC number is that of a company listed on a stock exchange.